Key result
TYRX envelope linked to ~89% fewer systemic or pocket infections following pacemaker or CRT-P procedures.
Why the study?
While the absorbable antibiotic-eluting envelope reduces CIED infection risk, data on its use in pacemaker and cardiac resynchronization therapy pacemaker devices are limited.
Does the absorbable antibiotic-eluting envelope reduce systemic and pocket infections in patients undergoing pacemaker or CRT-P implantation or revision?
Cohort (n=896)
Yes
Does the absorbable antibiotic-eluting envelope reduce systemic and pocket infections in patients undergoing pacemaker or CRT-P implantation or revision?
Effect estimate: IRR 0.11 (95% CI 0.05-0.23)
Absolute Event Rate: 0.3% vs 1.8%
p-value: p=<0.001
The use of an absorbable antibiotic-eluting envelope during pacemaker or CRT-P implantation or revision significantly reduces the risk of device-related infections in real-world practice.
Supports envelope use to curb infections in pacemaker/CRT-P procedures; leaves open need for randomized confirmation.
Abstract Background Infections related to cardiac implantable electrical devices (CIEDs) are among the most challenging and costly complications. While the absorbable antibiotic-eluting envelope has shown efficacy in reducing infection risk, data on its use in pacemaker (PM) and cardiac resynchronization therapy pacemaker devices (CRTP) are limited. Objectives To assess the effectiveness of the TYRX envelope in preventing systemic and pocket infections in patients undergoing PM or CRT-P implantation or revision. Methods This retrospective, multicenter analysis included 896 patients undergoing PM or CRTP implantation or revision between August 2020 and April 2024. Patients were categorized into two groups: the Envelope group (n=350), receiving the TYRX envelope, and the control group (n=546). Results Over a mean follow-up of 2.2 ± 2.1 years, systemic or pocket infections occurred in 1.2% of patients, with significantly fewer infections in the Envelope group (0.3%) compared to the control group (1.8%) (p=0.05). The envelope was associated with an 89% reduction in infection risk (Incidence Rate Ratio: 0.11; 95% CI:0.05–0.23;p<0.001). Kaplan-Meier analysis showed that at four years, the cumulative incidence of infection was 0.4% in the Envelope group versus 2.5% in the control group (Hazard Ratio: 7.36; p=0.03). Conclusions In patients with PMs and CRTPs use of the TYRX envelope is associated with significantly lower occurrence of device-related infections. This benefit was sustained over long-term follow-up, supporting its effectiveness in routine clinical practice.
No takes yet. Share an insight, caveat, or question.
Ziacchi et al. (2025) conducted a cohort in Pacemaker or CRT-P implantation or revision (n=896). TYRX envelope vs. Control group (no envelope) was evaluated on Systemic and pocket infections (IRR 0.11, 95% CI 0.05-0.23, p=<0.001). The TYRX envelope significantly reduced the risk of systemic or pocket infections compared to control (IRR 0.11; 95% CI 0.05-0.23; p<0.001) in patients undergoing pacemaker or CRT-P procedures.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: